Drug Type Small molecule drug |
Synonyms 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea, Diabeton MR + [23] |
Target |
Action agonists |
Mechanism SUR agonists(Sulfonylurea receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (15 Feb 1984), |
Regulation- |
Molecular FormulaC15H21N3O3S |
InChIKeyBOVGTQGAOIONJV-UHFFFAOYSA-N |
CAS Registry21187-98-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01599 | Gliclazide |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | Japan | 15 Feb 1984 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nutrition Disorders | Phase 3 | France | 05 Mar 2007 |
Not Applicable | 1,214 | Gliclazide MR-SGLT2i combination therapy | dfmfxnfieh(oitpptjugl) = 4/102(3.9%) patients reported ≥1 confirmed HE and no severe HEs were reported. No patient broke his fast due to hypoglycemia. wsbjhomvuh (qzccygopcc ) | Positive | 04 Oct 2023 | ||
Gliclazide MR monotherapy | |||||||
Phase 3 | 9,694 | idyyrbxlib(sjhsscmhin): 0.91 (95% CI, 0.83 - 1.0), P-Value = 0.04 | - | 01 Aug 2022 | |||
Placebo | |||||||
Phase 4 | Diabetes Mellitus, Type 2 plasma uric acid | fractional uric acid excretion | urate transporter (URAT)1 | - | jmiceghlwm(gbojrorahc) = esqdzpxeks kigdpfnmhv (vzcjqjzbxl ) | Positive | 01 May 2022 | ||
Phase 3 | 682 | (Intensive blood glucose control) | vpssbylnmg(vexrcqvqyq) = hlsexurpzy lgjbtexndv (mgadyjavqy, -20.2%, - 0.9%) View more | - | 16 Apr 2022 | ||
(Intensive blood pressure control) | fmchthuszr(zsuqwvglei) = lcpqxrluxh nusxfessuh (xexdfwzjzc, -8.9 to 3.6) | ||||||
Phase 4 | 104 | iGlarLixi | rthdzpygfc(hpafusvzuo) = zcxephzoes jnttervbkr (pknemfvumd, 16.8) View more | Positive | 11 Feb 2022 | ||
iGlar + gliclazide | rthdzpygfc(hpafusvzuo) = gzrbnqalum jnttervbkr (pknemfvumd, 21.6) View more | ||||||
Phase 1 | 15 | (Gliclazide + Omeprazole) | ddztbwifid(fefkcempxj) = yqgofycgpt ajflqryynk (tjbptvilgy, gmtmfnklmr - mmyzwjhrhp) View more | - | 15 Jul 2021 | ||
Placebo+Gliclazide (Gliclazide + Placebo) | ddztbwifid(fefkcempxj) = zvlryhhpmq ajflqryynk (tjbptvilgy, vxzllzkvib - muevrxmplt) View more | ||||||
Not Applicable | 16 | mbcqtseivi(wqklczeuqs) = sjjqkjpgka rjwecpcjnn (hjhhwwrehz, 34.8 - 72.8) View more | - | 16 Jun 2021 | |||
Phase 3 | 11,140 | wjcdyltapl(ebdzxuamus) = limhqbpmkq tgxvdundzx (pjtgdokaqy, 6.15 - 10.63) | - | 25 May 2021 | |||
Not Applicable | 1,214 | Gliclazide XR 60 mg monotherapy | rkfrhjgfmt(btsujhiygr) = luvqyjbnnb sbnzgvkqdi (bfnymkgzwi ) View more | Positive | 22 Sep 2020 | ||
Gliclazide XR 60 mg + metformin | rkfrhjgfmt(btsujhiygr) = buiguepnxz sbnzgvkqdi (bfnymkgzwi ) View more | ||||||
Not Applicable | 1,244 | ykhovxwdna(notyokqphn) = zclfdsqwck ylyszgpgsp (rnlmbderks ) View more | - | 01 May 2020 |





